Selvi Ersoy

Dr. Selvi Ersoy

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SESelvi Ersoy
Selvi Ersoy
HCHenry F. Chambers
Henry F. Chambers
RPRichard A. Proctor
Richard A. Proctor
ARAdriana E. Rosato
Adriana E. Rosato
NMNagendra N. Mishra
Nagendra N. Mishra
ABArnold Bayer
Arnold Bayer
Certain methicillin-resistant Staphylococcus aureus (MRSA) strains exhibit β-lactam susceptibility in vitro , ex vivo , and in vivo in the presence of NaHCO 3 (NaHCO 3 -responsive MRSA). Here, we investigate the impact of NaHCO 3 on factors required for PBP2a functionality.

20 October 2021 in Genes
Verified
Journal Article
Open access
PDF file
SESelvi Ersoy
Selvi Ersoy
BHBlake M. Hanson
Blake M. Hanson
RPRichard A. Proctor
Richard A. Proctor
CACesar A. Arias
Cesar A. Arias
TTTruc T. Tran
Truc T. Tran
ABArnold Bayer
Arnold Bayer
Methicillin-resistant Staphylococcus aureus (MRSA) infections represent a difficult clinical treatment issue. Recently, a novel phenotype was discovered amongst selected MRSA which exhibited enhanced β-lactam susceptibility in vitro in the presence of NaHCO3 (termed ‘NaHCO3-responsiveness’). This increased β-lactam susceptibility phenotype has been verified in both ex vivo and in vivo models. Mechanistic studies to-date have implicated NaHCO3-mediated repression of genes involved in the production, as well as maturation, of the alternative penicillin-binding protein (PBP) 2a, a necessary component of MRSA β-lactam resistance. Herein, we utilized RNA-sequencing (RNA-seq) to identify genes that were differentially expressed in NaHCO3-responsive (MRSA 11/11) vs. non-responsive (COL) strains, in the presence vs. absence of NaHCO3-β-lactam co-exposures. These investigations revealed that NaHCO3 selectively repressed the expression of a cadre of genes in strain 11/11 known to be a part of the sigB-sarA-agr regulon, as well as a number of genes involved in the anchoring of cell wall proteins in MRSA. Moreover, several genes related to autolysis, cell division, and cell wall biosynthesis/remodeling, were also selectively impacted by NaHCO3-OXA exposure in the NaHCO3-responsive strain MRSA 11/11. These outcomes provide an important framework for further studies to mechanistically verify the functional relevance of these genetic perturbations to the NaHCO3-responsiveness phenotype in MRSA.

9 September 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
SESelvi Ersoy
Selvi Ersoy
WRWarren E. Rose
Warren E. Rose
RPRobin Patel
Robin Patel
RPRichard A. Proctor
Richard A. Proctor
HCHenry G. Chambers
Henry G. Chambers
ABArnold Bayer
Arnold Bayer
Antimicrobial susceptibility testing (AST) is routinely used to establish predictive antibiotic resistance metrics to guide the treatment of bacterial pathogens. Recently, a novel phenotype termed “bicarbonate (NaHCO3)-responsiveness” was identified in a relatively high frequency of clinical MRSA strains, wherein isolates demonstrate in vitro “susceptibility” to standard β-lactams (oxacillin [OXA]; cefazolin [CFZ]) in the presence of NaHCO3, and in vivo susceptibility to these β-lactams in experimental endocarditis models. We investigated whether a targeted phenotypic-genotypic screening of MRSA could rule in or rule out NaHCO3 susceptibility upfront. We studied 30 well-characterized clinical MRSA bloodstream isolates, including 15 MIC-susceptible to CFZ and OXA in NaHCO3-supplemented Mueller–Hinton Broth (MHB); and 15 MIC-resistant to both β-lactams in this media. Using a two-tiered strategy, isolates were first screened by standard disk diffusion for susceptibility to a combination of amoxicillin-clavulanate [AMC]. Isolates then underwent genomic sequence typing: MLST (clonal complex [CC]); agr; SCCmec; and mecA promoter and coding region. The combination of AMC disk susceptibility testing plus mecA and spa genotyping was able to predict MRSA strains that were more or less likely to be NaHCO3-responsive in vitro, with a high degree of sensitivity and specificity. Validation of this screening algorithm was performed in six strains from the overall cohort using an ex vivo model of endocarditis. This ex vivo model recapitulated the in vitro predictions of NaHCO3-responsiveness vs. nonresponsiveness above in five of the six strains.

21 December 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
SESelvi Ersoy
Selvi Ersoy
BGBarbara Gonçalves
Barbara Gonçalves
GCGonçalo Cavaco
Gonçalo Cavaco
AMAdhar C. Manna
Adhar C. Manna
RSRita G. Sobral
Rita G. Sobral
ABArnold Bayer
Arnold Bayer
MRSA is generally viewed as resistant to standard β-lactam antibiotics. However, a NaHCO 3 -responsive phenotype is observed in a substantial proportion of clinical MRSA strains in vitro , i.e., isolates which demonstrate enhanced susceptibility to standard β-lactam antibiotics (e.g., oxacillin) in the presence of NaHCO 3 .

30 March 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
SESelvi Ersoy
Selvi Ersoy
LCLiana Chan
Liana Chan
MYMichael R. Yeaman
Michael R. Yeaman
HCHenry G. Chambers
Henry G. Chambers
RPRichard A. Proctor
Richard A. Proctor
ABArnold Bayer
Arnold Bayer
Methicillin-resistant Staphylococcus aureus (MRSA) regulates resistance to β-lactams via preferential production of an alternative penicillin-binding protein (PBP), PBP2a. PBP2a binds many β-lactam antibiotics with less affinity than PBPs which are predominant in methicillin-susceptible (MSSA) strains. A novel, rather frequent in vitro phenotype was recently identified among clinical MRSA bloodstream isolates, termed “NaHCO3-responsiveness”. This phenotype features β-lactam susceptibility of certain MRSA strains only in the presence of NaHCO3. Two distinct PBP2a variants, 246G and 246E, have been linked to the NaHCO3-responsive and NaHCO3-non-responsive MRSA phenotypes, respectively. To determine the mechanistic impact of PBP2a variants on β-lactam susceptibility, binding profiles of a fluorescent penicillin probe (Bocillin-FL) to each purified PBP2a variant were assessed and compared to whole-cell binding profiles characterized by flow cytometry in the presence vs. absence of NaHCO3. These investigations revealed that NaHCO3 differentially influenced the binding of the fluorescent penicillin, Bocillin-FL, to the PBP2a variants, with binding intensity and rate of binding significantly enhanced in the 246G compared to the 246E variant. Of note, the NaHCO3-β-lactam (oxacillin)-responsive JE2 strain, which natively harbors the 246G variant, had enhanced Bocillin-FL whole-cell binding following exposure to NaHCO3. This NaHCO3-mediated increase in whole-cell Bocillin-FL binding was not observed in the NaHCO3-non-responsive parental strain, COL, which contains the 246E PBP2a variant. Surprisingly, genetic swaps of the mecA coding sites between JE2 and COL did not alter the NaHCO3-enhanced binding seen in JE2 vs. COL. These data suggest that the non-coding regions of mecA may be involved in NaHCO3-responsiveness. This investigation also provides strong evidence that the NaHCO3-responsive phenotype in MRSA may involve NaHCO3-mediated increases in both initial cell surface β-lactam binding, as well as ultimate PBP2a binding of β-lactams.

21 June 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SESelvi Ersoy
Selvi Ersoy
AMAdhar C. Manna
Adhar C. Manna
RPRichard A. Proctor
Richard A. Proctor
HCHenry F. Chambers
Henry F. Chambers
EHEwan M. Harrison
Ewan M. Harrison
ACAmbrose Cheung
Ambrose Cheung
Methicillin-resistant Staphylococcus aureus (MRSA) strains are a leading cause of many invasive clinical syndromes, and pose treatment difficulties due to their in vitro resistance to most β-lactams on standard laboratory testing. A novel phenotype frequently identified in MRSA strains, termed ‘NaHCO 3 -responsiveness’, is a property whereby strains are susceptible in vitro to many β-lactams in the presence of NaHCO 3 .